The number of people with susceptibility test result for rifampicin in India
India: The number of people with susceptibility test result for rifampicin was 673,008 in 2021. ▲ Rising
Latest (2021)
673,008
Change on year
up 20.7%
World rank
1st
of 155 countries
All-time high
699,062
in 2019
All-time low
270,825
in 2017
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in India, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
India recorded 673,008 for the number of people with susceptibility test result for rifampicin in 2021.
Compared with earlier readings it is up 20.7% on the previous year and up 148.5% over five years.
India ranks 1st of 155 countries on this measure, in the top 10%.
The number of people with susceptibility test result for rifampicin in India, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 270,825 | — |
| 2018 | 364,292 | +34.5% |
| 2019 | 699,062 | +91.9% |
| 2020 | 557,456 | -20.3% |
| 2021 | 673,008 | +20.7% |
India compared with similar countries
- India's 673,008 is above the median for lower middle income countries, which is 2,804, 240.0× the median. (32 countries reporting)
- India's 673,008 is above the median for South Asia, which is 11,863, 56.7× the median. (5 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 444,726 | 270,825 | 699,062 | 3 |
| 2020s | 615,232 | 557,456 | 673,008 | 2 |
Countries ranked near India
More health data for India
- Un projection of annual infant deaths, annual growth rate -2.12 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4372 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,332 deaths per 1,000 people (2090)
- Number of infants who die before age 1 44,822 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 38 (2025)
- Population ages 00-04, female, annual growth rate -0.3809 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0372 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.5922 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in India?
- The number of people with susceptibility test result for rifampicin in India was 673,008 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in India?
- The highest recorded value was 699,062 in 2019.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in India?
- The lowest recorded value was 270,825 in 2017.
- How does India rank for the number of people with susceptibility test result for rifampicin?
- India ranks 1st out of 155 countries with data for 2021.
- Where does this India data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).